Rejoy Health vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W21 AI patient education for thyroid and chronic conditions at $125M valuation Sep 2024; $22.2M from Google, Harvard endowment, Gaingels/YC competing with Paloma Health for AI-driven medical knowledge accessibility for underdiagnosed chronic disease.
About
Rejoy Health is a San Francisco-based AI-powered healthcare platform — backed by Y Combinator (W21) with $22.2 million in total funding from Y Combinator, Google, Gaingels, and the Harvard University endowment fund, achieving a $125 million valuation in September 2024 — providing patients with chronic conditions (particularly thyroid disorders) with AI-driven medical knowledge accessibility tools and subscription-based treatment and management services that bridge the gap between patient symptoms, lab results, and clinical recommendations. Founded in 2020 by former Facebook and Microsoft engineers and launched through Y Combinator, Rejoy translates complex medical information into personalized, understandable patient guidance using artificial intelligence.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.